Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review.
J Comp Eff Res
; 13(7): e230158, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38869839
ABSTRACT
Aim:
The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality.Objective:
To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM.Method:
A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality.Results:
Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM.Conclusion:
The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Teste de Caminhada
/
Cardiomiopatias
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article